Temat: "Cholagogues and Choleretics" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment.
Autorzy:: MacDonald N; Department of Medicine, Thomas Jefferson University Hospital, 33 S 9 TH St, Suite 220, 19107, Philadelphia, PA, USA. .
Loh R; Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, 132 South 10th Street, Suite 480, 19107, Philadelphia, PA, USA.
Fenkel JM; Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, 132 South 10th Street, Suite 480, 19107, Philadelphia, PA, USA.
Sass DA; Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, 132 South 10th Street, Suite 480, 19107, Philadelphia, PA, USA.
Halegoua-DeMarzio D; Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, 132 South 10th Street, Suite 480, 19107, Philadelphia, PA, USA.; Pokaż więcej
Źródło:: BMC gastroenterology [BMC Gastroenterol] 2024 Jan 04; Vol. 24 (1), pp. 18. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:: Journal Article
MeSH Terms:: Cholangitis*/drug therapy
Liver Cirrhosis, Biliary*/drug therapy
Humans ; Cholagogues and Choleretics/therapeutic use ; Ursodeoxycholic Acid/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.
Autorzy:: Zhu H; Department of Gastroenterology, Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Zheng M; Department of Gastroenterology, Second Affiliated Hospital of Kunming Medical University, Kunming, China.
He H; Department of Gastroenterology, Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Lei H; School of Public Health Kunming Medical University, Kunming, China.
Tai W; Clinical Lab, Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Yang J; Department of Gastroenterology, Second Affiliated Hospital of Kunming Medical University, Kunming, China. .; Pokaż więcej
Źródło:: BMC gastroenterology [BMC Gastroenterol] 2023 Nov 17; Vol. 23 (1), pp. 400. Date of Electronic Publication: 2023 Nov 17.
Typ publikacji:: Journal Article
MeSH Terms:: Ursodeoxycholic Acid*/therapeutic use
Ursodeoxycholic Acid*/adverse effects
Liver Cirrhosis, Biliary*/drug therapy
Liver Cirrhosis, Biliary*/complications
Humans ; Retrospective Studies ; Cholagogues and Choleretics/therapeutic use ; Neutrophils ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Pharmaceutical suspensions of ursodeoxycholic acid for pediatric patients: in vitro and in vivo studies.
Autorzy:: Boscolo O; Departamento de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Salvo L; Departamento de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Dobrecky C; Departamento de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Fissore EN; Departamento de Industrias, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, ITAPROQ-UBA-CONICET, Buenos Aires, Argentina.; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Buontempo F; Departamento de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.; Servicio de Farmacia. Hospital de Pediatría Prof. Dr Juan Patricio. Garrahan, Buenos Aires, Argentina.
Tripodi V; Departamento de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Lucangioli SE; Departamento de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.; Pokaż więcej
Źródło:: Pharmaceutical development and technology [Pharm Dev Technol] 2021 Jun; Vol. 26 (5), pp. 599-609. Date of Electronic Publication: 2021 Apr 06.
Typ publikacji:: Comparative Study; Journal Article
MeSH Terms:: Cholagogues and Choleretics/*administration & dosage
Excipients/*chemistry
Ursodeoxycholic Acid/*administration & dosage
Administration, Oral ; Animals ; Biological Availability ; Chemistry, Pharmaceutical ; Cholagogues and Choleretics/chemistry ; Cholagogues and Choleretics/pharmacokinetics ; Drug Stability ; Drug Storage ; Humidity ; Male ; Rats ; Rats, Sprague-Dawley ; Rheology ; Solubility ; Suspensions ; Temperature ; Ursodeoxycholic Acid/chemistry ; Ursodeoxycholic Acid/pharmacokinetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study.
Autorzy:: Chang JI; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Department of Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Korea.
Kim JH; Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
Sinn DH; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Cho JY; Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea.
Kim KM; Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Oh JH; Department of Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
Park Y; Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea.
Sohn W; Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Goh MJ; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kang W; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Gwak GY; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Paik YH; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Choi MS; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee JH; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Koh KC; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Paik SW; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Pokaż więcej
Źródło:: Gut and liver [Gut Liver] 2023 Jul 15; Vol. 17 (4), pp. 620-628. Date of Electronic Publication: 2023 Mar 31.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Ursodeoxycholic Acid*/therapeutic use
Liver Cirrhosis, Biliary*/drug therapy
Liver Cirrhosis, Biliary*/pathology
Humans ; Cholagogues and Choleretics/therapeutic use ; Cohort Studies ; Republic of Korea ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Safety of fibrates in cholestatic liver diseases.
Autorzy:: Carrion AF; Division of Gastroenterology and Hepatology, University of Miami, Miami, FL, USA.
Lindor KD; Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA.; Office of University Provost, Arizona State University, Phoenix, AZ, USA.
Levy C; Division of Gastroenterology and Hepatology, University of Miami, Miami, FL, USA.; Pokaż więcej
Źródło:: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2021 Jun; Vol. 41 (6), pp. 1335-1343. Date of Electronic Publication: 2021 Mar 18.
Typ publikacji:: Journal Article; Systematic Review
MeSH Terms:: Cholagogues and Choleretics*/adverse effects
Liver Cirrhosis, Biliary*/drug therapy
Bezafibrate/adverse effects ; Fibric Acids/adverse effects ; Humans ; Ursodeoxycholic Acid/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Evaluation of acute and subacute toxicity of sodium taurodeoxycholate in rats.
Autorzy:: Choi HJ; Graduate School of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.; Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Yun JW; Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.
Kim YH; Wide River Institute of Immunology, Department of Microbiology and Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kwon E; Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Hyon MK; Graduate School of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.; Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Kim JY; Graduate School of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.; Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Che JH; Biomedical Center for Animal Resource and Development, Seoul National University College of Medicine, Seoul, Republic of Korea.
Ho Kim W; Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Seong SY; Wide River Institute of Immunology, Department of Microbiology and Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kang BC; Graduate School of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.; Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.; Biomedical Center for Animal Resource and Development, Seoul National University College of Medicine, Seoul, Republic of Korea.; Designed Animal and Transplantation Research Institute, Institute of GreenBio Science Technology, Seoul National University, Pyeongchang-gun, Gangwon-do, Republic of Korea.; Pokaż więcej
Źródło:: Drug and chemical toxicology [Drug Chem Toxicol] 2021 May; Vol. 44 (3), pp. 268-276. Date of Electronic Publication: 2019 Jun 19.
Typ publikacji:: Journal Article
MeSH Terms:: Cholagogues and Choleretics/*toxicity
Taurodeoxycholic Acid/*toxicity
Animals ; Chemical and Drug Induced Liver Injury/etiology ; Cholagogues and Choleretics/administration & dosage ; Dose-Response Relationship, Drug ; Edema/chemically induced ; Female ; Infusions, Intravenous ; Lethal Dose 50 ; Male ; Rats ; Rats, Sprague-Dawley ; Taurodeoxycholic Acid/administration & dosage ; Toxicity Tests, Acute ; Toxicity Tests, Subacute

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Role of mitochondria in the differential action of sodium deoxycholate and ursodeoxycholic acid on rat duodenum.
Autorzy:: Pérez A; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.
Rivoira MA; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.
Rodríguez V; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.
Marchionatti A; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.
Tolosa de Talamoni N; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.; Laboratorio 'Dr. Fernando Cañas', Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, INICSA (CONICET-Universidad Nacional de Córdoba), Pabellón Argentina, 2do. Piso, Ciudad Universitaria, 5000 Córdoba, Argentina.; Pokaż więcej
Źródło:: Canadian journal of physiology and pharmacology [Can J Physiol Pharmacol] 2021 Mar; Vol. 99 (3), pp. 270-277. Date of Electronic Publication: 2020 Jul 20.
Typ publikacji:: Journal Article
MeSH Terms:: Cholagogues and Choleretics/*pharmacology
Deoxycholic Acid/*pharmacology
Duodenum/*drug effects
Mitochondria/*metabolism
Ursodeoxycholic Acid/*pharmacology
Animals ; Calcium/pharmacokinetics ; Cholagogues and Choleretics/pharmacokinetics ; Citric Acid Cycle/drug effects ; Deoxycholic Acid/pharmacokinetics ; Electron Transport ; Intestinal Absorption/drug effects ; Male ; Mitochondrial Proton-Translocating ATPases/metabolism ; Organelle Biogenesis ; Oxidative Phosphorylation/drug effects ; Oxidative Stress ; Rats ; Rats, Wistar ; Superoxide Dismutase/metabolism ; Ursodeoxycholic Acid/pharmacokinetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Efficacy of ursodeoxycholic acid for primary biliary cholangitis: Experience from a tertiary care centre in Saudi Arabia.
Autorzy:: AlWabel AH; Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Peedikayil M; Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
AlNasser S; Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
AlHusaini K; Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
AlHekail O; Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Alqahtani SA; Department of Medicine, King Faisal Specialist Hospital & Research Centre; Organ Transplant Center, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
AlTraif IH; Hepatology Division, Department of Hepatobiliary Sciences and Organ Transplant Center, King Abdulaziz Medical City; King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
AlAshgar H; Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.; Pokaż więcej
Źródło:: Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2023 Mar-Apr; Vol. 29 (2), pp. 135-140.
Typ publikacji:: Journal Article
MeSH Terms:: Ursodeoxycholic Acid*/therapeutic use
Liver Cirrhosis, Biliary*/complications
Liver Cirrhosis, Biliary*/drug therapy
Liver Cirrhosis, Biliary*/diagnosis
Male ; Humans ; Female ; Middle Aged ; Cholagogues and Choleretics/therapeutic use ; Tertiary Care Centers ; Saudi Arabia/epidemiology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Efficacy and safety of ATX-101 as a treatment for submental fullness: A retrospective analysis of two aesthetic practices.
Autorzy:: Zarbafian M; Department of Dermatology & Skin Science, University of British Columbia, Vancouver, BC, Canada.
Karavan M; West Dermatology, Rancho Santa Margarita, CA, USA.
Greene R; Greene MD Plastic Surgery and Laser Center, Weston, FL, USA.
Fabi SG; Cosmetic Laser Dermatology, San Diego, CA, USA.; Department of Dermatology, University of California, San Diego, CA, USA.; Pokaż więcej
Źródło:: Journal of cosmetic dermatology [J Cosmet Dermatol] 2020 Jun; Vol. 19 (6), pp. 1328-1332. Date of Electronic Publication: 2019 Sep 25.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Cholagogues and Choleretics/*administration & dosage
Cosmetic Techniques/*adverse effects
Deoxycholic Acid/*administration & dosage
Lipolysis/*drug effects
Subcutaneous Fat/*drug effects
Adult ; Chin ; Cholagogues and Choleretics/adverse effects ; Deoxycholic Acid/adverse effects ; Esthetics ; Female ; Humans ; Injections, Subcutaneous/adverse effects ; Male ; Middle Aged ; Patient Satisfaction ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid.
Autorzy:: de Veer RC; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Harms MH; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Corpechot C; Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.
Thorburn D; The Sheila Sherlock Liver Centre, and UCL Institute of Liver and Digestive Health, The Royal Free Hospital, London, UK.
Invernizzi P; Division of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Janssen HLA; Toronto Centre for Liver disease, Toronto General Hospital, University Health Network, Toronto, Canada.
Battezzati PM; Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Nevens F; Department of Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Lindor KD; Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.; Arizona State University, College of Health Solutions, Phoenix, Arizona, USA.
Floreani A; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; Scientific Institute for Research, Hospitalization and Healthcare, Negrar, Verona, Italy.
Ponsioen CY; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, location Academic Medical Center, Amsterdam, The Netherlands.
Mayo MJ; Digestive and Liver diseases, UT Southwestern Medical Center, Dallas, Texas, USA.
Parés A; Liver Unit, Hospital Clínic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.
Mason AL; Division of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada.
Kowdley KV; Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle, WA, USA.
Trivedi PJ; Birmingham NIHR Biomedical Research Centre, and Centre for Liver Research, University of Birmingham, Birmingham, UK.
Hirschfield GM; Toronto Centre for Liver disease, Toronto General Hospital, University Health Network, Toronto, Canada.; Birmingham NIHR Biomedical Research Centre, and Centre for Liver Research, University of Birmingham, Birmingham, UK.
Bruns T; Department of Internal Medicine IV, Jena University Hospital, Friedrich Schiller University, Jena, Germany.; Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
Dalekos GN; Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece.
Gatselis NK; Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece.
Verhelst X; Department of Gastroenterology and Hepatology, Ghent University Hospital, Belgium.
Lammers WJ; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Hansen BE; Toronto Centre for Liver disease, Toronto General Hospital, University Health Network, Toronto, Canada.; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
van Buuren HR; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
van der Meer AJ; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.; Pokaż więcej
Corporate Authors:: Global PBC Study Group
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Nov; Vol. 56 (9), pp. 1408-1418. Date of Electronic Publication: 2022 Sep 22.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Liver Cirrhosis, Biliary*/diagnosis
Liver Cirrhosis, Biliary*/drug therapy
Liver Cirrhosis, Biliary*/surgery
Liver Transplantation*
Alkaline Phosphatase ; Cholagogues and Choleretics/therapeutic use ; Humans ; Ursodeoxycholic Acid/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Evidence for functional selectivity in TUDC- and norUDCA-induced signal transduction via α 5 β 1 integrin towards choleresis.
Autorzy:: Bonus M; Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Sommerfeld A; Clinic for Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Qvartskhava N; Clinic for Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Görg B; Clinic for Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Ludwig BS; Institute for Advanced Study and Center for Integrated Protein Science, Department of Chemistry, Technische Universität München, Garching, Germany.
Kessler H; Institute for Advanced Study and Center for Integrated Protein Science, Department of Chemistry, Technische Universität München, Garching, Germany.
Gohlke H; Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. .; John von Neumann Institute for Computing (NIC), Jülich Supercomputing Centre (JSC), and Institute for Complex Systems - Structural Biochemistry (ICS-6), Forschungszentrum Jülich GmbH, Jülich, Germany. .
Häussinger D; Clinic for Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2020 Apr 02; Vol. 10 (1), pp. 5795. Date of Electronic Publication: 2020 Apr 02.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: MAP Kinase Signaling System*
Cholagogues and Choleretics/*pharmacology
Integrin alpha5beta1/*metabolism
Liver/*metabolism
Taurochenodeoxycholic Acid/*pharmacology
Ursodeoxycholic Acid/*pharmacology
ATP Binding Cassette Transporter, Subfamily B, Member 11/metabolism ; Animals ; Binding Sites ; Cholagogues and Choleretics/chemistry ; ErbB Receptors/metabolism ; Integrin alpha5beta1/chemistry ; Liver/drug effects ; Male ; Molecular Docking Simulation ; Protein Binding ; Rats ; Rats, Wistar ; Taurochenodeoxycholic Acid/chemistry ; Ursodeoxycholic Acid/chemistry ; p38 Mitogen-Activated Protein Kinases/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve perinatal outcomes: protocol for a randomised controlled trial (PITCHES).
Autorzy:: Chappell LC; King's College London, London, UK. .
Chambers J; ICP Support, Sutton Coldfield, UK.
Dixon PH; King's College London, London, UK.
Dorling J; Dalhousie University, Halifax, Canada.
Hunter R; University College London, London, UK.
Bell JL; National Perinatal Epidemiology Unit Clinical Trials Unit, University of Oxford, Oxford, UK.
Bowler U; National Perinatal Epidemiology Unit Clinical Trials Unit, University of Oxford, Oxford, UK.
Hardy P; Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Juszczak E; National Perinatal Epidemiology Unit Clinical Trials Unit, University of Oxford, Oxford, UK.
Linsell L; National Perinatal Epidemiology Unit Clinical Trials Unit, University of Oxford, Oxford, UK.
Rounding C; National Perinatal Epidemiology Unit Clinical Trials Unit, University of Oxford, Oxford, UK.
Smith A; National Perinatal Epidemiology Unit Clinical Trials Unit, University of Oxford, Oxford, UK.
Williamson C; King's College London, London, UK.
Thornton JG; University of Nottingham, Nottingham, UK.; Pokaż więcej
Źródło:: Trials [Trials] 2018 Nov 27; Vol. 19 (1), pp. 657. Date of Electronic Publication: 2018 Nov 27.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Cholagogues and Choleretics/*therapeutic use
Cholestasis, Intrahepatic/*drug therapy
Pregnancy Complications/*drug therapy
Ursodeoxycholic Acid/*therapeutic use
Cholagogues and Choleretics/adverse effects ; Cholestasis, Intrahepatic/blood ; Cholestasis, Intrahepatic/diagnosis ; Cholestasis, Intrahepatic/mortality ; England ; Female ; Fetal Death/prevention & control ; Gestational Age ; Humans ; Infant, Newborn ; Multicenter Studies as Topic ; Perinatal Death/prevention & control ; Pregnancy ; Pregnancy Complications/blood ; Pregnancy Complications/diagnosis ; Pregnancy Complications/mortality ; Premature Birth/prevention & control ; Randomized Controlled Trials as Topic ; Stillbirth ; Time Factors ; Treatment Outcome ; Ursodeoxycholic Acid/adverse effects ; Wales
SCR Disease Name:: Intrahepatic Cholestasis of Pregnancy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
Autorzy:: Wunsch E; Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.
Raszeja-Wyszomirska J; Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.
Barbier O; Laboratory of Molecular Pharmacology, CHU Quebec and Faculty of Pharmacy, Laval University, Quebec, Canada.
Milkiewicz M; Department of Medical Biology, Pomeranian Medical University, Szczecin, Poland.
Krawczyk M; Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany;Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Milkiewicz P; Translational Medicine Group, Pomeranian Medical University, Szczecin;Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland. .; Pokaż więcej
Źródło:: Journal of gastrointestinal and liver diseases : JGLD [J Gastrointestin Liver Dis] 2018 Sep; Vol. 27 (3), pp. 273-279.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Quality of Life*
Cholagogues and Choleretics/*therapeutic use
Liver/*drug effects
Liver Cirrhosis, Biliary/*drug therapy
S-Adenosylmethionine/*therapeutic use
Ursodeoxycholic Acid/*therapeutic use
Adult ; Aged ; Alkaline Phosphatase/blood ; Biomarkers/blood ; Cholagogues and Choleretics/adverse effects ; Cholesterol/blood ; Fatigue/etiology ; Fatigue/prevention & control ; Female ; Humans ; Liver/metabolism ; Liver Cirrhosis, Biliary/blood ; Liver Cirrhosis, Biliary/complications ; Liver Cirrhosis, Biliary/diagnosis ; Middle Aged ; Pilot Projects ; Poland ; Proof of Concept Study ; Prospective Studies ; Pruritus/etiology ; Pruritus/prevention & control ; S-Adenosylmethionine/adverse effects ; Surveys and Questionnaires ; Time Factors ; Treatment Outcome ; Ursodeoxycholic Acid/adverse effects ; gamma-Glutamyltransferase/blood

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Machine learning in primary biliary cholangitis: A novel approach for risk stratification.
Autorzy:: Gerussi A; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy.
Verda D; Rulex Inc, Newton, Massachusetts, USA.
Bernasconi DP; Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Carbone M; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy.
Komori A; Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki, Japan.
Abe M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Inao M; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Namisaki T; Department of Gastroenterology, Nara Medical University, Nara, Japan.
Mochida S; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Yoshiji H; Department of Gastroenterology, Nara Medical University, Nara, Japan.
Hirschfield G; Toronto Centre for Liver Disease, Toronto Western & General Hospital, University Health Network, Toronto, Ontario, Canada.; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Lindor K; Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, United States.; Arizona State University, Phoenix, Arizona, United States.
Pares A; Liver Unit, Hospital Clínic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hospital Clinic de Barcelona, Barcelona, Spain.
Corpechot C; Centre de Référence des Maladies Inflammatoires des Voies Biliaires et des Hépatites auto-immunes, Hôpital Saint- Antoine, APHP-Sorbonne Université, Paris, France.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hôpital Saint-Antoine, Paris, France.
Cazzagon N; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Azienda Ospedale - Università Padova, Padova, Italy.
Floreani A; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.; Scientific Institute for Research, Hospitalization and Healthcare, Verona, Italy.
Marzioni M; Division of Gastroenterology and Hepatology, Ospedali Riuniti University Hospital, Ancona, Italy.
Alvaro D; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Vespasiani-Gentilucci U; Clinical Medicine and Hepatology Unit, Campus Bio-Medico University of Rome, Rome, Italy.
Cristoferi L; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy.; Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Valsecchi MG; Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Muselli M; Rulex Inc, Newton, Massachusetts, USA.; Institute of Electronics, Computer and Telecommunication Engineering, National Research Council of Italy, Genova, Italy.
Hansen BE; Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki, Japan.; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Tanaka A; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Invernizzi P; Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy.; Pokaż więcej
Źródło:: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2022 Mar; Vol. 42 (3), pp. 615-627. Date of Electronic Publication: 2022 Jan 07.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cholangitis*/complications
Liver Cirrhosis, Biliary*/drug therapy
Cholagogues and Choleretics/therapeutic use ; Humans ; Machine Learning ; Prognosis ; Risk Assessment ; Ursodeoxycholic Acid/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Alterations in gut microbiota and elevated serum bilirubin in primary biliary cholangitis patients treated with ursodeoxycholic acid.
Autorzy:: Han W; Department of Liver Disease Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Huang C; Second Department of liver disease center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Zhang Q; Department of Liver Disease Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Tao S; Department of Liver Disease Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Hu X; Department of Liver Disease Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Xu J; Department of Liver Disease Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Jiang R; Department of Liver Disease Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Xu B; Second Department of liver disease center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Liu Y; Second Department of liver disease center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Hou J; Department of Liver Disease Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China.; Pokaż więcej
Źródło:: European journal of clinical investigation [Eur J Clin Invest] 2022 Feb; Vol. 52 (2), pp. e13714. Date of Electronic Publication: 2021 Dec 09.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Gastrointestinal Microbiome*
Bilirubin/*blood
Cholagogues and Choleretics/*therapeutic use
Liver Cirrhosis, Biliary/*blood
Liver Cirrhosis, Biliary/*drug therapy
Liver Cirrhosis, Biliary/*microbiology
Ursodeoxycholic Acid/*therapeutic use
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Acquired palmoplantar keratoderma associated with primary biliary cholangitis: Complete and persistent resolution after ursodeoxycholic acid treatment.
Autorzy:: March-Rodriguez A; Department of Dermatology, Hospital del Mar-Parc de Salut Mar, Barcelona, Spain.
Marcantonio O; Department of Dermatology, Hospital del Mar-Parc de Salut Mar, Barcelona, Spain.
Olmos-Alpiste F; Department of Dermatology, Hospital del Mar-Parc de Salut Mar, Barcelona, Spain.
Pujol RM; Department of Dermatology, Hospital del Mar-Parc de Salut Mar, Barcelona, Spain.; Pokaż więcej
Źródło:: The Australasian journal of dermatology [Australas J Dermatol] 2022 Feb; Vol. 63 (1), pp. e49-e51. Date of Electronic Publication: 2021 Dec 14.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Cholagogues and Choleretics/*therapeutic use
Keratoderma, Palmoplantar/*drug therapy
Liver Cirrhosis, Biliary/*drug therapy
Ursodeoxycholic Acid/*therapeutic use
Female ; Humans ; Keratoderma, Palmoplantar/etiology ; Liver Cirrhosis, Biliary/complications ; Middle Aged

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial).
Autorzy:: Boerlage TCC; Department of internal medicine, MC Slotervaart, Amsterdam, the Netherlands.; Department of gastroenterology & hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.
Haal S; Department of internal medicine, MC Slotervaart, Amsterdam, the Netherlands.; Department of gastroenterology & hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.
Maurits de Brauw L; Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.
Acherman YIZ; Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.
Bruin S; Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.
van de Laar AWJM; Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.
Moes DE; Department of surgery, MC Slotervaart, Amsterdam, the Netherlands.
van Wagensveld BA; Department of surgery, OLVG, Amsterdam, the Netherlands.
de Vries CEE; Department of surgery, OLVG, Amsterdam, the Netherlands.
van Veen R; Department of surgery, OLVG, Amsterdam, the Netherlands.
Schouten R; Department of surgery, MC Zuiderzee, Lelystad, the Netherlands.
Dijkgraaf MG; Clinical Research Unit, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Fockens P; Department of gastroenterology & hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.
Gerdes VEA; Department of internal medicine, MC Slotervaart, Amsterdam, the Netherlands.; Department of vascular medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Voermans RP; Department of gastroenterology & hepatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands. .; Department of gastroenterology, MC Slotervaart, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands. .; Pokaż więcej
Źródło:: BMC gastroenterology [BMC Gastroenterol] 2017 Dec 20; Vol. 17 (1), pp. 164. Date of Electronic Publication: 2017 Dec 20.
Typ publikacji:: Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Cholagogues and Choleretics/*therapeutic use
Gallstones/*prevention & control
Gastric Bypass/*adverse effects
Postoperative Complications/*prevention & control
Ursodeoxycholic Acid/*therapeutic use
Cholagogues and Choleretics/adverse effects ; Cholagogues and Choleretics/economics ; Clinical Protocols ; Cost-Benefit Analysis ; Double-Blind Method ; Follow-Up Studies ; Gallstones/etiology ; Humans ; Obesity, Morbid/surgery ; Postoperative Complications/etiology ; Quality of Life ; Ursodeoxycholic Acid/adverse effects ; Ursodeoxycholic Acid/economics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Deoxycholic Acid Modulates Cell-Junction Gene Expression and Increases Intestinal Barrier Dysfunction.
Autorzy:: Zeng H; United States Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA.
Safratowich BD; United States Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA.
Cheng WH; Department of Food Science, Nutrition and Health Promotion, Mississippi State University, Starkville, MS 39762, USA.
Larson KJ; United States Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA.
Briske-Anderson M; United States Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND 58203, USA.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2022 Jan 22; Vol. 27 (3). Date of Electronic Publication: 2022 Jan 22.
Typ publikacji:: Journal Article
MeSH Terms:: Cholagogues and Choleretics/*pharmacology
Colon/*metabolism
Deoxycholic Acid/*pharmacology
Gene Expression Regulation/*drug effects
Intercellular Junctions/*metabolism
Intestinal Mucosa/*metabolism
Caco-2 Cells ; Cell Proliferation ; Colon/drug effects ; Humans ; Intercellular Junctions/drug effects ; Intercellular Junctions/genetics ; Intestinal Mucosa/drug effects ; Permeability

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
Autorzy:: Sorda JA; Department of Gastroenterology and Hepatology, University Hospital 'José de San Martín', Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
González Ballerga E; Department of Gastroenterology and Hepatology, University Hospital 'José de San Martín', Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Barreyro FJ; Biotechnology Institute of Misiones (INBIOMIS), National University of Misiones, National Scientific and Technical Research Council (CONICET), Posadas, Argentina.
Avagnina A; Department of Pathology, University Hospital 'José de San Martín', Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Carballo P; Department of Pathology, University Hospital 'José de San Martín', Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Paes de Lima A; Department of Pathology, University Hospital 'José de San Martín', Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Daruich J; Department of Gastroenterology and Hepatology, University Hospital 'José de San Martín', Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Nov; Vol. 54 (9), pp. 1202-1212. Date of Electronic Publication: 2021 Sep 29.
Typ publikacji:: Journal Article
MeSH Terms:: Liver Cirrhosis, Biliary*/drug therapy
Ursodeoxycholic Acid*/therapeutic use
Bezafibrate/therapeutic use ; Biopsy ; Cholagogues and Choleretics/therapeutic use ; Drug Therapy, Combination ; Follow-Up Studies ; Humans ; Longitudinal Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Tauroursodeoxycholic Acid Decreases Keloid Formation by Reducing Endoplasmic Reticulum Stress as Implicated in the Pathogenesis of Keloid.
Autorzy:: Kim S; Department of Plastic and Reconstructive Surgery, College of Medicine, Chungnam National University, Daejeon 35015, Korea.
Lee SE; Research Institute for Medicinal Sciences, College of Medicine, Chungnam National University, Daejeon 35015, Korea.
Yi S; Research Institute for Medicinal Sciences, College of Medicine, Chungnam National University, Daejeon 35015, Korea.
Jun S; Center for Research Equipment, Korea Basic Science Institute, Daejeon 34133, Korea.; Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea.
Yi YS; Center for Research Equipment, Korea Basic Science Institute, Daejeon 34133, Korea.
Nagar H; Department of Physiology, College of Medicine, Chungnam National University, Daejeon 35015, Korea.
Kim CS; Department of Physiology, College of Medicine, Chungnam National University, Daejeon 35015, Korea.
Shin C; Department of Plastic and Reconstructive Surgery, College of Medicine, Chungnam National University, Daejeon 35015, Korea.
Yeo MK; Department of Pathology, College of Medicine, Chungnam National University, Daejeon 35015, Korea.
Kang YE; Research Institute for Medicinal Sciences, College of Medicine, Chungnam National University, Daejeon 35015, Korea.; Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 35015, Korea.
Oh SH; Department of Plastic and Reconstructive Surgery, College of Medicine, Chungnam National University, Daejeon 35015, Korea.; Brain Research Institute, College of Medicine, Chungnam National University, Daejeon 35015, Korea.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Oct 05; Vol. 22 (19). Date of Electronic Publication: 2021 Oct 05.
Typ publikacji:: Journal Article
MeSH Terms:: Cholagogues and Choleretics/*pharmacology
Endoplasmic Reticulum Stress/*drug effects
Keloid/*prevention & control
Taurochenodeoxycholic Acid/*pharmacology
Adult ; Animals ; Apoptosis ; Case-Control Studies ; Female ; Humans ; Keloid/etiology ; Keloid/metabolism ; Keloid/pathology ; Male ; Rabbits ; Signal Transduction

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 21.

Tytuł:: Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
Autorzy:: Soret PA; Paris, France.
Lam L; Paris, France.
Carrat F; Paris, France.
Smets L; Leuven, Belgium.
Berg T; Leipzig, Germany.
Carbone M; Monza, Italy.
Invernizzi P; Monza, Italy.
Leroy V; Grenoble, France.
Trivedi P; Birmingham, UK.
Cazzagon N; Padova, Italy.
Weiler-Normann C; Hamburg, Germany.
Alric L; Toulouse, France.
Rosa-Hezode I; Créteil, France.
Heurgué A; Reims, France.
Cervoni JP; Besançon, France.
Dumortier J; Lyon, France.
Potier P; Orléans, France.
Roux O; Clichy, France.
Silvain C; Poitiers, France.
Bureau C; Toulouse, France.
Anty R; Nice, France.
Larrey D; Montpellier, France.
Levy C; Miami, USA.
Pares A; Barcelona, Spain.
Schramm C; Hamburg, Germany.
Nevens F; Leuven, Belgium.
Chazouillères O; Paris, France.
Corpechot C; Paris, France.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 May; Vol. 53 (10), pp. 1138-1146. Date of Electronic Publication: 2021 Mar 25.
Typ publikacji:: Journal Article
MeSH Terms:: Liver Cirrhosis, Biliary*/drug therapy
Chenodeoxycholic Acid/analogs & derivatives ; Cholagogues and Choleretics/therapeutic use ; Fibric Acids/therapeutic use ; Humans ; Retrospective Studies ; Ursodeoxycholic Acid/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 22.

Tytuł:: A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis.
Autorzy:: Zuo P; PAREXEL International, Durham, North Carolina, USA.
Dobbins RL; Cempra Pharmaceuticals, Chapel Hill, North Carolina, USA.
O'Connor-Semmes RL; PAREXEL International, Durham, North Carolina, USA.
Young MA; PAREXEL International, Durham, North Carolina, USA.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2016 Aug; Vol. 5 (8), pp. 418-26. Date of Electronic Publication: 2016 Aug 18.
Typ publikacji:: Journal Article
MeSH Terms:: Systems Analysis*
Cholagogues and Choleretics/*metabolism
Liver Cirrhosis, Biliary/*metabolism
Ursodeoxycholic Acid/*metabolism
Administration, Oral ; Bile Acids and Salts/metabolism ; Cholagogues and Choleretics/administration & dosage ; Databases, Factual/statistics & numerical data ; Humans ; Ileum/drug effects ; Ileum/metabolism ; Liver Cirrhosis, Biliary/drug therapy ; Random Allocation ; Ursodeoxycholic Acid/administration & dosage

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 23.

Tytuł:: Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model.
Autorzy:: Gozukara I; a Department of Obstetric and Gynecology , School of Medicine, Mustafa Kemal University , Hatay , Turkey .
Dokuyucu R; b Department of Physiology , Mustafa Kemal University , Hatay , Turkey .
Özgür T; c Department of Pathology , Mustafa Kemal University , Hatay , Turkey .
Özcan O; d Department of Biochemistry , Mustafa Kemal University , Hatay , Turkey .
Pınar N; e Department of Pharmacology , Mustafa Kemal University , Hatay , Turkey , and.
Kurt RK; a Department of Obstetric and Gynecology , School of Medicine, Mustafa Kemal University , Hatay , Turkey .
Kucur SK; f Department of Obstetric and Gynecology , Dumlupinar University, School of Medicine , Kütahya , Turkey.
Dolapcioglu K; a Department of Obstetric and Gynecology , School of Medicine, Mustafa Kemal University , Hatay , Turkey .; Pokaż więcej
Źródło:: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology [Gynecol Endocrinol] 2016 Jun; Vol. 32 (6), pp. 492-7. Date of Electronic Publication: 2016 Jan 15.
Typ publikacji:: Journal Article
MeSH Terms:: Cholagogues and Choleretics/*pharmacology
Ovary/*drug effects
Polycystic Ovary Syndrome/*blood
Polycystic Ovary Syndrome/*drug therapy
Ursodeoxycholic Acid/*pharmacology
Animals ; Cholagogues and Choleretics/administration & dosage ; Disease Models, Animal ; Female ; Rats ; Rats, Wistar ; Ursodeoxycholic Acid/administration & dosage

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 24.

Tytuł:: Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.
Autorzy:: Gomez E; Madrid, Spain.
Garcia Buey L; Madrid, Spain.
Molina E; Santiago, Spain.
Casado M; Almeria, Spain.
Conde I; Valencia, Spain.
Berenguer M; Valencia, Spain.
Jorquera F; León, Spain.
Simón MA; Zaragoza, Spain.
Olveira A; Madrid, Spain.
Hernández-Guerra M; Vila Real, Portugal.
Mesquita M; Porto, Portugal.
Presa J; Porto, Portugal.
Costa-Moreira P; Santa Cruz de Tenerife, Spain.
Macedo G; Santa Cruz de Tenerife, Spain.
Arenas JI; San Sebastian, Spain.
Manuel Sousa J; Sevilla, Spain.
Ampuero J; Sevilla, Spain.
Morillas RM; Barcelona, Spain.
Santos A; Coimbra, Spain.
De Carvalho A; Coimbra, Spain.
Uriz J; Navarra, Spain.
Carrión JA; Barcelona, Spain.
Luisa Gutiérrez M; Madrid, Spain.
Pérez-Fernández E; Madrid, Spain.
Fernández-Rodríguez CM; Madrid, Spain.; Pokaż więcej
Corporate Authors:: IBER-PBC leading Cooperative Group
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Feb; Vol. 53 (4), pp. 519-530. Date of Electronic Publication: 2020 Dec 12.
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Liver Cirrhosis, Biliary*/drug therapy
Ursodeoxycholic Acid*/adverse effects
Chenodeoxycholic Acid/analogs & derivatives ; Cholagogues and Choleretics/adverse effects ; Humans ; Prospective Studies ; Spain

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 25.

Tytuł:: Combination of submicroemulsion and phospholipid complex for novel delivery of ursodeoxycholic acid.
Autorzy:: Ma YQ; Department of Pharmaceutics, the 94th Hospital of PLA , Nanchang , China.
Li G
Xu JH
Zhang J
Zhang ZZ
Xiao HY
Li XF; Pokaż więcej
Źródło:: Pharmaceutical development and technology [Pharm Dev Technol] 2014 May; Vol. 19 (3), pp. 363-72. Date of Electronic Publication: 2013 May 01.
Typ publikacji:: Journal Article
MeSH Terms:: Cholagogues and Choleretics/*administration & dosage
Emulsions/*chemistry
Phospholipids/*chemistry
Ursodeoxycholic Acid/*administration & dosage
Administration, Oral ; Animals ; Biological Availability ; Cholagogues and Choleretics/chemistry ; Cholagogues and Choleretics/pharmacokinetics ; Male ; Particle Size ; Rats ; Rats, Wistar ; Ursodeoxycholic Acid/chemistry ; Ursodeoxycholic Acid/pharmacokinetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Cholagogues and Choleretics"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język